Reimbursement Review Reports


( Last Updated : August 1, 2021)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

 

Brand Name Generic name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
TBD Entrectinib Withdrawn Jul 29, 2019
TBD Trastuzumab Cancelled
Venclexta Venetoclax Withdrawn Jul 8, 2016
Xeljanz tofacitinib Cancelled
Tecentriq Atezolizumab Withdrawn Oct 2, 2019
Zytiga Abiraterone Withdrawn Feb 25, 2019
Truxima Rituximab Cancelled
Admelog Insulin lispro Cancelled
TBD Rituximab Cancelled
Firazyr icatibant CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed